It is important to note that trials for locally advanced HNSCC incorporating EGFR inhibition (cetuximab, erlotinib, panitumumab) with chemoradiation failed to show an advantage in PFS or OS over chemoradiation alone [55]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.